A Molecular View of Anti-ErbB Monoclonal Antibody Therapy

Daniel J. Leahy

Research output: Contribution to journalArticle

Abstract

Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much about how they function. In this issue of Cancer Cell, Schmiedel et al. report structural and functional studies of the anti-EGFR monoclonal antibody Matuzumab. They show that Matuzumab binds and inhibits EGFR in a manner distinctive from that of other therapeutic anti-EGFR antibodies and suggest that combination therapies with Matuzumab and other antibodies may prove beneficial.

Original languageEnglish (US)
Pages (from-to)291-293
Number of pages3
JournalCancer Cell
Volume13
Issue number4
DOIs
StatePublished - Apr 8 2008

Fingerprint

Epidermal Growth Factor Receptor
Monoclonal Antibodies
Antibodies
Therapeutics
Neoplasms
matuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

A Molecular View of Anti-ErbB Monoclonal Antibody Therapy. / Leahy, Daniel J.

In: Cancer Cell, Vol. 13, No. 4, 08.04.2008, p. 291-293.

Research output: Contribution to journalArticle

Leahy, Daniel J. / A Molecular View of Anti-ErbB Monoclonal Antibody Therapy. In: Cancer Cell. 2008 ; Vol. 13, No. 4. pp. 291-293.
@article{6364e2ae23fd4a61a774a8a21a1e5493,
title = "A Molecular View of Anti-ErbB Monoclonal Antibody Therapy",
abstract = "Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much about how they function. In this issue of Cancer Cell, Schmiedel et al. report structural and functional studies of the anti-EGFR monoclonal antibody Matuzumab. They show that Matuzumab binds and inhibits EGFR in a manner distinctive from that of other therapeutic anti-EGFR antibodies and suggest that combination therapies with Matuzumab and other antibodies may prove beneficial.",
author = "Leahy, {Daniel J.}",
year = "2008",
month = "4",
day = "8",
doi = "10.1016/j.ccr.2008.03.010",
language = "English (US)",
volume = "13",
pages = "291--293",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - A Molecular View of Anti-ErbB Monoclonal Antibody Therapy

AU - Leahy, Daniel J.

PY - 2008/4/8

Y1 - 2008/4/8

N2 - Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much about how they function. In this issue of Cancer Cell, Schmiedel et al. report structural and functional studies of the anti-EGFR monoclonal antibody Matuzumab. They show that Matuzumab binds and inhibits EGFR in a manner distinctive from that of other therapeutic anti-EGFR antibodies and suggest that combination therapies with Matuzumab and other antibodies may prove beneficial.

AB - Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much about how they function. In this issue of Cancer Cell, Schmiedel et al. report structural and functional studies of the anti-EGFR monoclonal antibody Matuzumab. They show that Matuzumab binds and inhibits EGFR in a manner distinctive from that of other therapeutic anti-EGFR antibodies and suggest that combination therapies with Matuzumab and other antibodies may prove beneficial.

UR - http://www.scopus.com/inward/record.url?scp=41249097332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41249097332&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2008.03.010

DO - 10.1016/j.ccr.2008.03.010

M3 - Article

C2 - 18394550

AN - SCOPUS:41249097332

VL - 13

SP - 291

EP - 293

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 4

ER -